RTP Mobile Logo
Visiting Professors: Colorectal Cancer Edition, Issue 1, 2011
Released February 2011

Featuring Dr Charles S Fuchs’ perspective on a day spent visiting patients with colorectal cancer in the clinic of a community oncologist. (Audio Content)

CE Disclosures and Faculty Information


    Individualized treatment decisions for patients with early, locally advanced or metastatic colorectal cancer are driven by disease-specific and patient-specific characteristics. Published results from ongoing trials lead to the emergence of new therapeutic agents and regimens, novel biomarkers influencing treatment selection and alterations to existing management algorithms. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To provide clinicians with therapeutic strategies to address the disparate needs of patients with colorectal cancer, the Visiting Professors audio series uses an innovative, case-based approach that unites the perspectives of leading colorectal cancer investigators and community oncologists as they explore the intricacies of treatment decision-making. Upon completion of this CME activity, medical oncologists should be able to formulate an up-to-date and more complete approach to the care of patients with colorectal cancer.

    • Use case-based learning, innovative communication strategies and shared clinical insight to provide comprehensive and compassionate oncology care.
    • Counsel patients with colorectal cancer about the clinical benefits of dietary, exercise and lifestyle changes.
    • Communicate to patients the risks and benefits of adjuvant chemotherapy based on the clinicopathologic characteristics of their cancer.
    • Develop up-to-date clinical management strategies for metastatic colorectal cancer, incorporating chemotherapy and anti-VEGF and anti-EGFR antibodies.
    • Formulate a treatment plan for synchronous or metachronous primary colorectal cancer and liver-only metastases.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains an audio component. The participant should listen to the audio MP3s.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY Dr Glynn had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr FuchsAdvisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Genomic Health Inc, ImClone Systems Incorporated, Roche Laboratories Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are
    not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Bristol-Myers Squibb Company, Genentech BioOncology and Lilly USA LLC.

    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date:
    February 2011
    Expiration date: February 2012

Acknowledge and close

Listen to audio: